Glycotope is a clinical-stage immuno-oncology company built on world-leading glyco-biology expertise. The company draws on its long experience in glyco-biology to create highly specific mAbs targeting glyco-epitopes, and glyco-optimized mAbs with enhanced performance.
Glycotope has a growing pipeline of high-value cancer therapies focused around the antibody gatipotuzumab, which targets the novel glyco-epitope target TA-MUC1. Its lead clinical program is in Phase Ib in combination with Tomuzotuximab, a glyco-optimized second-generation anti-EGFR mAb.
In addition the company has a mature and growing pipeline of proprietary cancer therapies incl. PM-CD3-GEX® - a bispecific T cell engaging antibody recognizing tumor-specific TA-MUC1 on tumor cells and a specific receptor (CD3) on T cells and PM-IL15-GEX® - a TA-MUC1 targeting antibody fused to the cytokine Interleukin-15 to turn the immune desert at the tumor site into an immunologically hot tumor to induce tumor killing.
Glycotope provides a wide range of services for biopharmaceutical companies incl.